Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Medigene AG Announces Appointment of Dr. Kirsty Crame, MD, as Head of Clinical Research & Development
March 20, 2023 06:00 ET
|
Medigene AG
Martinsried/Munich, March 20, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene to present first pre-clinical data for MDG1015 with poster presentation at AACR 2023 Annual Meeting
March 16, 2023 05:00 ET
|
Medigene AG
Martinsried/Munich, March 16, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG to report full year 2022 financial results on March 29, 2023
March 15, 2023 11:47 ET
|
Medigene AG
Martinsried/Munich, March 15, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene Amends 2022 Financial Guidance
March 10, 2023 12:00 ET
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, March 10, 2023 (GLOBE NEWSWIRE) -- The Executive Management Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage...
Medigene Presents First Results for Automated Manufacturing of T Cell Receptor Engineered T Cells
February 23, 2023 08:00 ET
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard) is an early-stage immuno-oncology platform company focusing on the...
Medigene to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
February 22, 2023 10:00 ET
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the...
Medigene to Present at the 6th Annual CAR-TCR Summit Europe in London
February 15, 2023 09:00 ET
|
Medigene AG
MARTINSRIED, Germany and MUNICH, Germany, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the...
Medigene AG Appoints Pamela Keck as Vice President of Investor Relations and Corporate Communications
February 01, 2023 11:35 ET
|
Medigene AG
MARTINSRIED and MUNICH, Germany, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and...
Medigene Receives $3 Million Milestone Payment from 2seventy bio
January 18, 2023 11:35 ET
|
Medigene AG
Milestone payment is related to the establishment of 2seventy bio’s strategic partnership with JW TherapeuticsPayment provides further validation of Medigene’s end-to-end platform MARTINSRIED,...
Medigene Announces Strategy and Corporate Update
November 15, 2022 11:35 ET
|
Medigene AG
Company strategy focused on developing differentiated TCR-T therapies from its proprietary “end-to-end” platform to target solid tumors with high unmet needPipeline expansion and acceleration of lead...